Craneware (LON:CRW)‘s stock had its “buy” rating restated by equities researchers at Berenberg Bank in a research note issued on Tuesday, Digital Look reports. They presently have a GBX 3,600 ($47.04) price target on the stock. Berenberg Bank’s target price would indicate a potential upside of 20.00% from the stock’s current price.
Separately, Peel Hunt reissued a “buy” rating on shares of Craneware in a research note on Monday, June 17th.
Shares of LON:CRW opened at GBX 3,000 ($39.20) on Tuesday. The firm has a market cap of $789.86 million and a P/E ratio of 48.31. The company has a 50-day simple moving average of GBX 2,961.99. Craneware has a 1 year low of GBX 1,615 ($21.10) and a 1 year high of GBX 3,650 ($47.69).
Craneware plc, together with its subsidiaries, develops, licenses, and supports computer software for the healthcare industry in the United States. The company offers patient engagement solutions, such as InSight Medical Necessity, a software-as-a-service (SaaS) solution that provides medical necessity validation for United States payers and advance beneficiary notice creation; and Trisus Patient Payment, which provides hospitals and health systems to modernize patient payment.
Further Reading: Can systematic risk be avoided?
Receive News & Ratings for Craneware Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Craneware and related companies with MarketBeat.com's FREE daily email newsletter.